Prime Medicine logo

Prime Medicine Share Price Today

(NASDAQ: PRME)

Prime Medicine share price is $2.31 & ₹200.90 as on 6 Mar 2025, 2.30 'hrs' IST

$2.31

0.1

(4.76%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Prime Medicine share price in Dollar and Rupees. Guide to invest in Prime Medicine stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Prime Medicine, along with analyst recommendations, forecasts, and comprehensive financials.

Prime Medicine share price movements

  • Today's Low: $2.15
    Today's High: $2.33

    Day's Volatility :7.53%

  • 52 Weeks Low: $2.20
    52 Weeks High: $8.88

    52 Weeks Volatility :75.23%

Prime Medicine (PRME) Returns

PeriodPrime Medicine, Inc.Index (Russel 2000)
3 Months
-25.76%
0.0%
6 Months
-41.2%
0.0%
1 Year
-73.81%
0.0%
3 Years
-85.65%
-11.6%

Prime Medicine (PRME) Key Statistics

in dollars & INR

Previous Close
$2.205
Open
$2.21
Today's High
$2.325
Today's Low
$2.15
Market Capitalization
$289.2M
Today's Volume
$154.8K
52 Week High
$8.88
52 Week Low
$2.15
Revenue TTM
$3.0M
EBITDA
$-196.3M
Earnings Per Share (EPS)
$-1.63
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-136.88%

How to invest in Prime Medicine Stock (PRME) from India?

It is very easy for Indian residents to invest directly in Prime Medicine from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Prime Medicine stock in both Indian Rupees (INR) and US Dollars (USD). Search for Prime Medicine or PRME on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Prime Medicine or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Prime Medicine shares which would translate to 0.376 fractional shares of Prime Medicine as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Prime Medicine, in just a few clicks!

Returns in Prime Medicine (PRME) for Indian investors in Rupees

The Prime Medicine stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Prime Medicine investment value today

Current value as on today

₹32,397

Returns

₹67,603

(-67.6%)

Returns from Prime Medicine Stock

₹72,565 (-72.57%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Prime Medicine (PRME)

67%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Prime Medicine Stock from India on INDmoney has increased by 67% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Prime Medicine

  • Alphabet Inc

    11.48%

  • ARK Investment Management LLC

    3.93%

  • BlackRock Inc

    3.45%

  • T. Rowe Price Investment Management,Inc.

    3.03%

  • FMR Inc

    2.90%

  • Vanguard Group Inc

    2.79%

Analyst Recommendation on Prime Medicine

Buy

    76%Buy

    23%Hold

    0%Sell

Based on 17 Wall street analysts offering stock ratings for Prime Medicine(by analysts ranked 0 to 5 stars)

Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
10
10
Hold
4
4
4
Sell
0
0
0

Analyst Forecast on Prime Medicine Stock (PRME)

What analysts predicted

Upside of 458.92%

Target:

$12.91

Current:

$2.31

Insights on Prime Medicine Stock (Ticker Symbol: PRME)

  • Price Movement

    In the last 1 year, PRME stock has moved down by -72.7%
  • PRME vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 135.0%
  • Price to Sales

    ForPRME every $1 of sales, investors are willing to pay $88.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

Prime Medicine Technicals Summary

Sell

Neutral

Buy

Prime Medicine is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Prime Medicine (PRME) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Prime Medicine, Inc. logo
-16.79%
-41.2%
-73.81%
-85.65%
-85.65%
Regeneron Pharmaceuticals, Inc. logo
1.3%
-41.29%
-30.51%
9.2%
42.38%
Beone Medicines Ltd logo
15.19%
34.31%
61.3%
43.16%
68.1%
Vertex Pharmaceuticals Incorporated logo
3.37%
3.77%
18.06%
106.43%
121.36%
Alnylam Pharmaceuticals, Inc. logo
-11.52%
-3.4%
62.32%
49.04%
120.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Prime Medicine, Inc. logo
NA
NA
NA
-1.11
-1.37
-0.52
NA
1.2
Regeneron Pharmaceuticals, Inc. logo
17.85
17.85
1.03
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.33
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Prime Medicine, Inc. logo
Buy
$289.2M
-85.65%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$74.9B
42.38%
17.85
31.07%
Beone Medicines Ltd logo
NA
$28.5B
68.1%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.1B
121.36%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.5B
120.93%
NA
-12.37%

About Prime Medicine

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.
Organization
Prime Medicine
Employees
0
CEO
Dr. Keith Michael Gottesdiener M.D., Ph.D.
Industry
Miscellaneous

Management People of Prime Medicine

NameTitle
Dr. Keith Michael Gottesdiener M.D., Ph.D.
President, CEO, Secretary & Director
Dr. Ann L. Lee Ph.D.
Chief Technical Officer
Dr. Jeremy S. Duffield M.D., Ph.D.
Chief Scientific Officer
Dr. Andrew Anzalone M.D., Ph.D.
Co-Founder & Head of Prime Editing Platform
Dr. David R. Liu Ph.D.
Co-Founder & Member of Scientific Advisory Board
Dr. Allan Reine M.D.
Chief Financial Officer
Dr. Meredith Goldwasser
Senior VP and Head of Strategy & Corporate Operations
Ms. Carman Alenson CPA, M.B.A.
Senior VP of Finance & Chief Accounting Officer
Dr. Karen Brown J.D., Ph.D.
Senior Vice President of Intellectual Property & Legal Affairs
Ms. Niamh Alix
Chief Human Resources Officer

Important FAQs about investing in PRME Stock from India :

What is Prime Medicine share price today?

Prime Medicine share price today stands at $2.31, Open: $2.21 ; Previous Close: $2.21 ; High: $2.33 ; Low: $2.15 ; 52 Week High: $8.88 ; 52 Week Low: $2.20.

The stock opens at $2.21, after a previous close of $2.21. The stock reached a daily high of $2.33 and a low of $2.15, with a 52-week high of $8.88 and a 52-week low of $2.20.

Can Indians buy Prime Medicine shares?

Yes, Indians can invest in the Prime Medicine (PRME) from India.

With INDmoney, you can buy Prime Medicine at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Prime Medicine at zero transaction cost.

How can I buy Prime Medicine shares from India?

It is very easy to buy Prime Medicine from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Prime Medicine (PRME) be purchased?

Yes, you can buy fractional shares of Prime Medicine with INDmoney app.

What are the documents required to start investing in Prime Medicine stocks?

To start investing in Prime Medicine, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Prime Medicine Stock (PRME)?

Today’s highest price of Prime Medicine (PRME) is $2.33.

Today’s lowest price of Prime Medicine (PRME) is $2.15.

What is today's market capitalisation of Prime Medicine?

Today's market capitalisation of Prime Medicine PRME is 289.2M

What is the 52 Week High and Low Range of Prime Medicine Stock (PRME)?

  • 52 Week High

    $8.88

  • 52 Week Low

    $2.20

What are the historical returns of Prime Medicine (PRME)?

  • 1 Month Returns

    -16.79%

  • 3 Months Returns

    -41.2%

  • 1 Year Returns

    -73.81%

  • 5 Years Returns

    -85.65%

Who is the Chief Executive Officer (CEO) of Prime Medicine ?

Dr. Keith Michael Gottesdiener M.D., Ph.D. is the current Chief Executive Officer (CEO) of Prime Medicine.